reviewSignal Transduction and Targeted TherapyMar 20, 2020GOLD OA

Comprehensive review of targeted therapy for colorectal cancer

YXYuanhong XieYCYingxuan ChenJFJing‐Yuan Fang

Shanghai Jiao Tong University · Renji Hospital · +1 more institution

PubMed
Indexed incrossrefdoajpubmed

Abstract

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have long been the first choices for cancer patients. However, the prognosis of CRC has never been satisfying, especially for patients with metastatic lesions. Targeted therapy is a new optional approach that has successfully prolonged overall survival for CRC patients. Following successes with the anti-EGFR (epidermal growth factor receptor) agent cetuximab and the anti-angiogenesis agent bevacizumab, new agents blocking different critical pathways as well as immune checkpoints are emerging at an unprecedented rate. Guidelines…

Citation impact

1,655
total citations
FWCI
79.93
Percentile
100%
References
521
Citations per year

Authors

3

Topics & keywords

Topics
Keywords
  • Cetuximab
  • Bevacizumab
  • Medicine
  • Colorectal cancer
  • Targeted therapy
  • Oncology
  • Cancer
  • Epidermal growth factor receptor
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding